Descriptors and administrative fields exactly as published in the CMS HCPCS quarterly file.
Billing context: J-codes
Units are reported in multiples of the dosage in the code descriptor.
One HCPCS billing unit of J7682
300 MG
Medicare payment limit per unit (Q4 2026): $11.404
| Setting | Max units / day | Adjudication (MAI) | CMS rationale |
|---|---|---|---|
| Practitioner services (professional claims) | 2 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | Prescribing Information |
| Facility outpatient hospital services | 0Not reportable in this setting | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | CMS Policy |
| DME supplier services | 112 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. |
Medicare Part B drug payment limits per billing unit, by quarter, from the CMS payment limit (ASP) files.
Current Medicare Part B payment limit · Q4 2026
$11.404per 300 MG
Effective Oct 1, 2026 – Dec 31, 2026 · ASP methodology (per CMS file) · based on Q2 2026 ASP data · coinsurance 20.000%
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q4 2026 | Oct 1, 2026 – Dec 31, 2026 | $11.404 | 300 MG | 20% | −7.3% | — |
| Q3 2026 | Jul 1, 2026 – Sep 30, 2026 | $12.305 | 300 MG | 20% | +58.4% |
Medicare hospital outpatient (OPPS) · Q4 2026
M Not billable to the MAC by hospitals
Washington Apple Health · professional claims
AAC = actual acquisition cost, based on NDC or invoice; BR = by report; NC = not covered; DC = not covered, see a different code; DP = covered under another program (see comments); PA = prior authorization; EPA = expedited prior authorization (see the billing guide); CPA = contractor prior authorization (Qualis). For professional claims; hospital-administered drugs are paid under HCA's outpatient (OPPS/EAPG) rules.
Packages CMS assigns to this code in its NDC–HCPCS crosswalks, with billable units per package. Only official crosswalk rows are shown.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Derived $ / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|---|
| 60687-0731-83 | Tobramycin inhalationAmerican Health Packaging | 5 × 30 | 1 | 30 | $342.12 | ASP | Q4 2024 – Q4 2026 | ListedTobramycin |
| 65162-0914-46 | Tobramycin inhalationAmneal Pharmaceuticals, LLC | 5 × 56 | 1 | 56 | $638.62 | ASP | Q1 2021 – Q4 2026 | ListedTobramycin |
| 10122-0820-28 | BethkisChiesi USA, Inc. | 4 × 28 | 1 | 28 | $319.31 | ASP | Q1 2021 – Q4 2026 | ListedBethkis |
| 10122-0820-56 | BethkisChiesi USA, Inc. | 4 × 56 | 1 | 56 | $638.62 | ASP | Q1 2021 – Q4 2026 | ListedBethkis |
| 43598-0605-56 | Tobramycin inhalationDr. Reddy's Laboratories Inc. | 5 × 56 | 1 | 56 | $638.62 | ASP | Q1 2021 – Q4 2026 | ListedTobramycin Inhalation Solution |
| 43598-0605-58 | Tobramycin inhalationDr. Reddy's Laboratories Inc. | 5 × 56 | 1 | 56 | $638.62 | ASP | Q2 2021 – Q4 2026 | ListedTobramycin Inhalation Solution |
| 70644-0899-99 | Tobramycin inhalationGenericus, Inc. | 5 × 56 | 1 | 56 | $638.62 | ASP | Q1 2021 – Q4 2026 | ListedTobramycin Inhalation Solution Pak |
| 70756-0604-56 | Tobramycin inhalationLifestar Pharma | 5 × 56 | 1 | 56 | $638.62 | ASP | Q2 2024 – Q4 2026 | ListedTobramycin |
| 70756-0617-56 | TobramycinLifestar Pharma | 4 × 56 | 1 | 56 | $638.62 | ASP | Q3 2023 – Q4 2026 | ListedTobramycin |
| 68180-0962-56 | Tobramycin inhalationLupin Pharmaceuticals, Inc. | 5 × 56 | 1 | 56 | $638.62 | ASP | Q2 2024 – Q4 2026 | ListedTobramycin |
| 42571-0408-92 | Tobramycin inhalationMicro Labs Limited | 5 × 56 | 1 | 56 | $638.62 | ASP | Q1 2026 – Q4 2026 | ListedTobramycin |
| 16714-0119-03 | Tobramycin inhalationNorthstar RxLLC | 5 × 56 | 1 | 56 | $638.62 | ASP | Q1 2021 – Q4 2026 | Not found |
| 72603-0430-56 | Tobramycin inhalationNorthstar RxLLC | 5 × 56 | 1 | 56 | $638.62 | ASP | Q3 2025 – Q4 2026 | ListedTobramycin |
| 72603-0630-56 | Tobramycin inhalationNorthstar RxLLC | 4 × 56 | 1 | 56 | $638.62 | ASP | Q2 2025 – Q4 2026 | ListedTobramycin |
| 24492-0850-56 | Kitabis PAKPARI Respiratory Equipment | 5 × 56 | 1 | 56 | $638.62 | ASP | Q1 2021 – Q4 2026 | ListedKitabis Pak |
| 66993-0195-94 | TobramycinPrasco Laboratories | 4 × 56 | 1 | 56 | $638.62 | ASP | Q1 2021 – Q4 2026 | ListedTobramycin inhalation |
| 76204-0029-56 | Tobramycin inhalationRitedose Pharmaceuticals, LLC | 5 × 56 | 1 | 56 | $638.62 | ASP | Q2 2026 – Q4 2026 | ListedTobramycin |
| 47335-0171-49 | Tobramycin inhalationSun Pharmaceutical Global FZE. | 5 × 56 | 1 | 56 | $638.62 | ASP | Q1 2026 – Q4 2026 | ListedTobramycin |
| 00093-3750-28 | TobramycinTeva Pharmaceuticals USA, Inc. | 4 × 28 | 1 | 28 | $319.31 | ASP | Q1 2021 – Q4 2026 | Excluded listingTobramycin |
| 00093-3750-63 | TobramycinTeva Pharmaceuticals USA, Inc. | 4 × 56 | 1 | 56 | $638.62 | ASP | Q1 2021 – Q4 2026 | Excluded listingTobramycin |
| 00093-4085-63 | Tobramycin inhalationTeva Pharmaceuticals USA, Inc. | 5 × 56 | 1 | 56 | $638.62 | ASP | Q1 2021 – Q4 2026 | ListedTobramycin |
| 49502-0345-73 | TobiViatris Specialty LLC | 5 × 56 | 1 | 56 | $638.62 | ASP | Q1 2023 – Q4 2026 | Not found |
Derived calculation “Derived $ / NDC” = billable units per NDC × the current payment limit. It is arithmetic for orientation, not a payment amount.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|
| 17478-0340-38 | Tobramycin inhalationAKORN | 5 × 56 | 1 | 56 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file |
Medicare coverage is set nationally (NCDs) and by each Medicare Administrative Contractor (LCDs and Billing & Coding articles). These links open the official documents.
Verification neededCodeRx links to coverage documents instead of copying them: CMS distributes their code lists under AMA, ADA, and AHA license terms that limit reuse. Medicare Advantage, Medicaid, and commercial plans set their own coverage and prior-authorization rules.
Changes detected between the CMS quarterly HCPCS files CodeRx has imported.
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q1 2023 | In earliest ingested file | N — No maintenance | Added date Jan 1, 2000 |
All imported releases, checksums, and import reports are listed on the data sources page.
Disclaimer. This application provides informational coding and reimbursement reference data. It does not constitute legal, clinical, coding, or billing advice. Codes, payment amounts, payer rules, and coverage policies can change. Verify all information with current CMS publications, the applicable payer, and your organization’s compliance policies before submitting a claim. CodeRx is not affiliated with or endorsed by CMS, FDA, Medicare, or any payer.
| Prescribing Information |
An MUE is the most units CMS expects for this code for one patient on one date of service by the same provider in most correctly reported claims. CMS MUE program
| — |
| Q2 2026 | Apr 1, 2026 – Jun 30, 2026 | $7.766 | 300 MG | 20% | −37.7% | — |
|---|
| Q1 2026 | Jan 1, 2026 – Mar 31, 2026 | $12.470 | 300 MG | 20% | −23.1% | — |
|---|
| Q4 2025 | Oct 1, 2025 – Dec 31, 2025 | $16.216 | 300 MG | 20% | +12.2% | — |
|---|
| Q3 2025 | Jul 1, 2025 – Sep 30, 2025 | $14.457 | 300 MG | 20% | −2.3% | — |
|---|
| Q2 2025 | Apr 1, 2025 – Jun 30, 2025 | $14.803 | 300 MG | 20% | −7.5% | — |
|---|
| Q1 2025 | Jan 1, 2025 – Mar 31, 2025 | $16.003 | 300 MG | 20% | +0.3% | — |
|---|
| Q4 2024 | Oct 1, 2024 – Dec 31, 2024 | $15.952 | 300 MG | 20% | −6.4% | — |
|---|
| Q3 2024 | Jul 1, 2024 – Sep 30, 2024 | $17.037 | 300 MG | 20% | +3.1% | — |
|---|
| Q2 2024 | Apr 1, 2024 – Jun 30, 2024 | $16.532 | 300 MG | 20% | −24.1% | — |
|---|
| Q1 2024 | Jan 1, 2024 – Mar 31, 2024 | $21.794 | 300 MG | 20% | −9.5% | — |
|---|
| Q4 2023 | Oct 1, 2023 – Dec 31, 2023 | $24.076 | 300 MG | 20% | −18.7% | — |
|---|
| Q3 2023 | Jul 1, 2023 – Sep 30, 2023 | $29.624 | 300 MG | 20% | +17.3% | — |
|---|
| Q2 2023 | Apr 1, 2023 – Jun 30, 2023 | $25.262 | 300 MG | 20% | −13.4% | — |
|---|
| Q1 2023 | Jan 1, 2023 – Mar 31, 2023 | $29.179 | 300 MG | — | +25.5% | — |
|---|
| Q4 2022 | Oct 1, 2022 – Dec 31, 2022 | $23.250 | 300 MG | — | −16.3% | — |
|---|
| Q3 2022 | Jul 1, 2022 – Sep 30, 2022 | $27.774 | 300 MG | — | +16.8% | — |
|---|
| Q2 2022 | Apr 1, 2022 – Jun 30, 2022 | $23.771 | 300 MG | — | −12.0% | — |
|---|
| Q1 2022 | Jan 1, 2022 – Mar 31, 2022 | $27.005 | 300 MG | — | −30.0% | — |
|---|
| Q4 2021 | Oct 1, 2021 – Dec 31, 2021 | $38.584 | 300 MG | — | +11.1% | — |
|---|
| Q3 2021 | Jul 1, 2021 – Sep 30, 2021 | $34.744 | 300 MG | — | +16.1% | — |
|---|
| Q2 2021 | Apr 1, 2021 – Jun 30, 2021 | $29.925 | 300 MG | — | −29.9% | — |
|---|
| Q1 2021 | Jan 1, 2021 – Mar 31, 2021 | $42.670 | 300 MG | — | — | — |
|---|
| 00078-0494-71 | TobiMYLAN SPECIALTY, L.P. | 5 × 56 | 1 | 56 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file | Excluded listingTobi |
|---|
| 00781-7171-56 | Tobramycin inhalationSANDOZ | 5 × 56 | 1 | 56 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file | Excluded listingTobramycin |
|---|